Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.
New research from Oregon Health & Science University for the first time reveals the function of a little-understood junction between cells in the brain that could have important treatment implications for conditions ranging from multiple sclerosis to Alzheimer's disease, to a type of brain cancer known as glioma.
The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis.
A study led by Dr. Hyun Kyoung Lee, associate professor at Baylor College of Medicine and investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, has discovered a new biological mechanism to regenerate and repair myelin, a protective sheath that insulates neuronal fibers and plays a vital role in ensuring rapid and accurate neurotransmission.
Patients often experience functional decline after an ischemic stroke, especially due to the brain's resistance to regenerate after damage.
Researchers use an established murine model of cortical inflammatory demyelination to investigate the effects of vitamin D.
Treating a mouse model of multiple sclerosis with the pregnancy hormone estriol reversed the breakdown of myelin in the brain's cortex, a key region affected in multiple sclerosis, according to a new UCLA Health study.
A decade after UC San Francisco scientists identified an over-the-counter antihistamine as a treatment for multiple sclerosis, researchers have developed an approach to measure the drug's effectiveness in repairing the brain, making it possible to also assess future therapies for the devastating disorder.
A University of Alberta researcher is one step closer to demonstrating the potential of a brain molecule called fractalkine to halt and even reverse the effects of multiple sclerosis and other neurodegenerative diseases.
Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such as multiple sclerosis, announced today it has entered into an exclusive worldwide license agreement with UCB.
Neurological diseases often begin with an inflammatory process and the degradation of the so-called myelin layer, which surrounds the nerve fibers (axons) like a protective insulating layer.
Huntington's disease – a hereditary and fatal genetic disorder – has long been considered a neuronal disease due to the permanent loss of medium spiny motor neurons, the death of which over time is responsible for the clinical hallmarks of the disease: involuntary movements, problems with coordination, cognitive decline, depression, and psychosis.
Osteocalcin (OCN) is a multifunctional bone-derived hormone that modulates numerous physiological activities. OCN can cross the blood brain barrier (BBB) and thus play critical roles in neuronal and brain development.
In the nearly 1 million Americans living with multiple sclerosis, the fatty substance that insulates the nerves of the central nervous system—called myelin—is damaged.
Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not.
A team led by a biomedical scientist at the University of California, Riverside, reports a drug -- an estrogen receptor ligand called indazole chloride (IndCl) -- has the potential to improve vision in patients with multiple sclerosis, or MS.
Seema Tiwari-Woodruff, a professor of biomedical sciences in the School of Medicine at the University of California, Riverside, and her colleagues have received a grant of $373,000 from the National Multiple Sclerosis Society for a project in which her lab will select the five best candidate compounds to speed up nerve impulses, a promising new avenue to treat multiple sclerosis.
A research team led by neurobiologist Professor Claire Jacob has identified an important mechanism that can be used to control the restoration of myelin sheaths following traumatic injury and in degenerative diseases.
Researchers from the University of Colorado School of Medicine have identified a new way that cells in the central nervous system regenerate and repair following damage.
Multiple sclerosis, characterized by increasing muscle weakness and paralysis, has a number of treatments that help stall progression of the disease when used early on in the disease.
Mohamad Khazaei, Ph.D., scientific associate in Dr. Michael Fehlings' lab at Krembil Research Institute, Toronto, is the latest recipient of STEM CELLS Translational Medicine's (SCTM) Young Investigator Award.